| Literature DB >> 24295811 |
Zheng Fan1, Jiahui Wang2, Mihye Ahn3, Yael Shiloh-Malawsky4, Nizar Chahin4, Sandra Elmore5, C Robert Bagnell5, Kathy Wilber6, Hongyu An6, Weili Lin6, Hongtu Zhu3, Martin Styner7, Joe N Kornegay8.
Abstract
The goal of this study was to assess whether magnetic resonance imaging (MRI) biomarkers can quantify disease progression in golden retriever muscular dystrophy (GRMD) via a natural history study. The proximal pelvic limbs of ten GRMD and eight normal dogs were scanned at 3, 6, and 9-12 months of age. Several MRI imaging and texture analysis biomarkers were quantified in seven muscles. Almost all MRI biomarkers readily distinguished GRMD from control dogs; however, only selected biomarkers tracked with longitudinal disease progression. The biomarkers that performed best were full-length muscle volume and a texture analysis biomarker, termed heterogeneity index. The biceps femoris, semitendinosus and cranial sartorius muscles showed differential progression in GRMD versus control dogs. MRI features in GRMD dogs showed dynamic progression that was most pronounced over the 3- to 6-month period. Volumetric biomarkers and water map values correlated with histopathological features of necrosis/regeneration at 6-months. In conclusion, selected MRI biomarkers (volume and heterogeneity index) in particular muscles (biceps femoris, semitendinosus, and cranial sartorius) adjusted for age effect allow distinction of differential longitudinal progression in GRMD dogs. These biomarkers may be used as surrogate outcome measures in preclinical GRMD trials.Entities:
Keywords: Biomarker; GRMD; MRI; Muscular dystrophy; T2 mapping; Texture analysis
Mesh:
Year: 2013 PMID: 24295811 PMCID: PMC4065593 DOI: 10.1016/j.nmd.2013.10.005
Source DB: PubMed Journal: Neuromuscul Disord ISSN: 0960-8966 Impact factor: 4.296